Psoriasis and Skin Barrier Dysfunction: The Role of Gentle Cleansers and Moisturizers in Treating Psoriasis

August 2023 | Volume 22 | Issue 8 | 773 | Copyright © August 2023


Published online July 31, 2023

Leon Kircik MD FAADa, Andrew F. Alexis MD MPH FAADb, Anneke Andriessen PhDc, Collin Blattner MD FAADd, Brad P. Glick MD DO MPH FAADe, Charles W. Lynde MD FRCPCf, Linda Stein Gold MD FAADg

aIcahn School of Medicine, Mount Sinai, New York, NY, Dermatology, Indiana University Medical Center, Indianapolis, IN, Physicians Skin Care, PLLC, Louisville, KY, DermResearch, PLLC, Louisville, KY
bWeill Cornell Medical College, New York, NY
cRadboud UMC, Nijmegen and Andriessen Consultants, Malden, The Netherlands 
dDepartment of Dermatology, Clear Choice Dermatology LLC & Great Skin Medical Consulting LLC, Portland, OR 
eAAD Board of Directors, Dermatology Residency Program Director Larkin Palm Springs Hospital PI, GSI Clinical Research, ASDS Advocacy Ambassador, Miami, FL
fDepartment of Medicine University of Toronto, Toronto, ON, Canada; Lynderm Research, Markham, ON, Canada gClinical Research, Department of Dermatology, Henry Ford Health, Detroit, MI



alone or in combination with other topical therapies, are limited and do not allow for evaluating possible clinical relevance. 

Statement 2: Guidelines and algorithms rarely mention skincare for psoriasis patients, demonstrating an important need gap.

Guidelines and algorithms for psoriasis patients discuss prescription treatments.11-15,20-22,26-29 There is a role for topical prescription therapy in all patients with psoriasis if the disease is limited (>5% body surface area), as a single treatment, and, in more extensive cases, as an adjunct therapy.23,24 The main topical prescription classes are corticosteroids, Vitamin D3 analogs, combination steroids, vitamin D products, topical calcineurin inhibitors, topical retinoids, and a combination of topical steroids and retinoids.23-29 

Topical prescription therapy can be combined with ultraviolet B (UVB) phototherapy (narrowband [NB] or broadband [BB]), or psoralen plus ultraviolet A (PUVA).23-25 For more severe cases systemic treatment is available, such as with biologics (adalimumab, etanercept, infliximab, secukinumab, and ustekinumab.23-27 One guideline mentioned salicylic acid-containing skincare added to topical or systemic therapy to remove scales. More robust data on skincare use are needed to have skincare incorporated into guidelines and pathways.

Statement 3: Skincare may play a role in the management of psoriasis, regardless of disease severity or the therapy, both as adjuvant treatment of acute psoriasis and for follow-up treatment of healing skin during asymptomatic periods.